Phase 1 Clinical Evaluation Update Voyageur announced on January 13, 2025 that the company commenced testing of its current barium contrast media formulations in human subjects, to ensure efficacy ...

Their leadership will be pivotal in developing Voyageur's next-generation MRI contrast agents with the goal of achieving clinical readiness. Voyageur remains committed to bringing its barium ...

On January 15, 2025, the Company issued a news release recapping significant achievements in 2024, including that it had secured a CAD $2.7 million sales distribution contract for SmoothX 2% Barium ...

Antispasmodics, such as glucagon and anticholinergic agents, improve the diagnostic accuracy of double-contrast barium meal examinations (DCBMs); however, they have been associated with adverse ...

The Alberta Innovates grant funding accelerates a transformative clinical performance evaluation, benchmarking the natural Frances Creek barium contrast media against existing synthetic barium ...

Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company") wishes to clarify the terms of a distribution and wholesaling ...